Email Alert RSS
Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Mei GUAN, Chun-mei BAI. Medical Treatment for Biliary Tract Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 325-333. DOI: 10.3969/j.issn.1674-9081.20190247
Citation: Mei GUAN, Chun-mei BAI. Medical Treatment for Biliary Tract Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 325-333. DOI: 10.3969/j.issn.1674-9081.20190247
shu

Medical Treatment for Biliary Tract Cancer

  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    BAI Chun-mei Tel: 86-10-69158760， E-mail: baichunmei@pumch.cn

  • Received Date: November 07, 2019
  • Issue Publish Date: May 29, 2020
    Graphical Abstract
    • Abstract
  • Curative resection remains the most effective and the only potentially curative therapy for biliary tract cancer(BTC). Most of the patients with BTC present with an advanced (inoperable or metastatic) disease, and the relapse rate is high in those undergoing curative resection. In Meta-analysis, compared with surgery only, there was a significant improvement in overall survival with any adjuvant therapy after surgery. Although the BILCAP study failed to meet its primary endpoint by intention to treat analysis, a survival benefit was seen in a preplanned sensitivity analysis. Gemcitabine combined with cisplatin is still the first-line chemotherapy for patients with advanced disease. Gemcitabine with TS-1, or gemcitabine with cisplatin and TS-1 become an alternative to the first-line chemotherapy. IDH1 mutations and FGFR2 fusions have been positioned as the two main driving alterations in intrahepatic cholangiocarcinoma, and are the hot spots for targeted therapies. Immunotherapy alone or combined with other therapy is still on the way in the treatment of advanced BTC. This review discussed the past, present and exciting future of the medical treatments of cholangiocarcinoma.
    • FullText(HTML)
    • References (65)
  • [1]
    Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013[J]. JAMA Oncol,2015,1:505-527. DOI: 10.1001/jamaoncol.2015.0735
    [2]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin,2015,65:5-29. DOI: 10.3322/caac.21254
    [3]
    Andia ME, Hsing AW, Andreotti G, et al. Geographic variation of gallbladder cancer mortality and risk factors in Chile:a population-based ecologic study[J]. Int J Cancer, 2008,123:1411-1416. DOI: 10.1002/ijc.23662
    [4]
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide:geographical distribution and risk factors[J]. Int J Cancer, 2006,118:1591-1602. DOI: 10.1002/ijc.21683
    [5]
    Marcano-Bonilla L, Mohamed EA, Mounajjed T, et al. Biliary tract cancers:epidemiology, molecular pathogenesis and genetic risk associations[J]. Chin Clin Oncol,2016,5:61. DOI: 10.21037/cco.2016.10.09
    [6]
    Patel T. Worldwide trends in mortality from biliary tract malignancies[J]. BMC Cancer, 2002, 2:10. DOI: 10.1186/1471-2407-2-10
    [7]
    Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24:189-199. DOI: 10.1055/s-2004-828895
    [8]
    Sohal DP, Shrotriya S, Abazeed M, et al. Molecular characteristics of biliary tract cancer[J]. Crit Rev Oncol Hematol,2016, 107:111-118. DOI: 10.1016/j.critrevonc.2016.08.013
    [9]
    Goetze TO. Gallbladder carcinoma:Prognostic factors and therapeutic options[J]. World J Gastroenterol,2015,21:12211-12217. DOI: 10.3748/wjg.v21.i43.12211
    [10]
    Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer:a retrospective single-center study[J]. Ann Surg Oncol,2013,20:318-324. DOI: 10.1245/s10434-012-2312-8
    [11]
    Agrawal S, Mohan L, Mourya C, et al.Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases[J]. Asian Pac J Cancer Prev,2016, 17:2137-2140. DOI: 10.7314/APJCP.2016.17.4.2137
    [12]
    Selvakumar VP, Zaidi S, Pande P, et al. Resection after neoadjuvant chemotherapy in advanced carcinoma of the gallbladder:a retrospective study[J]. Indian J Surg Oncol,2015,6:16-19. DOI: 10.1007/s13193-015-0377-0
    [13]
    Chaudhari VA, Ostwal V, Patkar S, et al. Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable" gallbladder cancer:the need to define indications[J]. HPB (Oxford),2018,20:841-847. DOI: 10.1016/j.hpb.2018.03.008
    [14]
    Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg,2018,105:839-847. DOI: 10.1002/bjs.10641
    [15]
    Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer-A systematic review[J]. Eur J Surg Oncol,2019,45:83-91. DOI: 10.1016/j.ejso.2018.08.020
    [16]
    Gangopadhyay A, Nath P, Biswas J. Reduced Dose Intensity of Chemotherapy may not Lead to Inferior Palliation in Locally Advanced Carcinoma of the Gall Bladder:An Experience from a Regional Cancer Centre in Eastern India[J]. J Gastrointest Cancer, 2015,46:297-300. DOI: 10.1007/s12029-015-9742-z
    [17]
    Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma:A propensity score matched analysis[J]. Eur J Surg Oncol,2019,45:1432-1438. DOI: 10.1016/j.ejso.2019.03.023
    [18]
    Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J].Cancer,2002,95:1685-1695. DOI: 10.1002/cncr.10831
    [19]
    Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer:a systematic review and meta-analysis[J].J Clin Oncol,2012,30:1934-1940. DOI: 10.1200/JCO.2011.40.5381
    [20]
    Rangarajan K, Simmons G, Manas D, et al. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery:A systematic review and meta-analysis[J]. Eur J Surg Oncol, 2020,46:684-693. DOI: 10.1016/j.ejso.2019.11.499
    [21]
    Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP):a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol,2019,20:663-673. DOI: 10.1016/S1470-2045(18)30915-X
    [22]
    Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI):A Randomized Phase Ⅲ Study[J]. J Clin Oncol,2019,37:658-667.
    [23]
    Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observa-tion in resected bile duct cancer[J]. Br J Surg,2018,105:192-202. DOI: 10.1002/bjs.10776
    [24]
    Cho M, Wang-Gillam A, Myerson R, et al. A phase Ⅱ study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma[J]. HPB (Oxford),2015,17:587-593. DOI: 10.1111/hpb.12413
    [25]
    Nakachi K, Konishi M, Ikeda M, et al. A randomized Phase Ⅲ trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer:Japan Clinical Oncology Group Study (JCOG1202, ASCOT)[J]. Jpn J Clin Oncol,2018,48:392-405. DOI: 10.1093/jjco/hyy004
    [26]
    Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma(ACTICCA-1 trial)-a randomized, multidisciplinary, multinational phase Ⅲ trial[J]. BMC Cancer,2015,15:564. DOI: 10.1186/s12885-015-1498-0
    [27]
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med,2010,362:1273-1281. DOI: 10.1056/NEJMoa0908721
    [28]
    Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer:The FUGA-BT (JCOG1113) Randomized Phase Ⅲ Clinical Trial[J]. Ann Oncol,2019,30:1950-1958. DOI: 10.1093/annonc/mdz402
    [29]
    Sahai V, Catalano PJ, Zalupski MM, et al. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma:A Phase 2 Clinical Trial[J]. JAMA Oncol,2018,4:1707-1712. DOI: 10.1001/jamaoncol.2018.3277
    [30]
    Yoo C, Han B, Kim HS, et al. Multicenter Phase Ⅱ Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer[J]. Cancer Res Treat,2018,50:1324-1330. DOI: 10.4143/crt.2017.526
    [31]
    Wang X, Hu J, Cao G, et al. Phase Ⅱ Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma[J]. Radiology,2017,283:580-589. DOI: 10.1148/radiol.2016160572
    [32]
    Zheng Y, Tu X, Zhao P, et al. A randomised phase Ⅱ study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin[J]. Br J Cancer,2018,119:291-295. DOI: 10.1038/s41416-018-0138-2
    [33]
    Schweitzer N, Kirstein MM, Kratzel AM, et al. Second-line chemotherapy in biliary tract cancer:Outcome and prognostic factors[J]. Liver Int,2019,39:914-923. DOI: 10.1111/liv.14063
    [34]
    Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups[J]. Oncotarget,2014, 5:2839-2852. DOI: 10.18632/oncotarget.1943
    [35]
    Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway[J]. Nat Genet,2014,46:872-876. DOI: 10.1038/ng.3030
    [36]
    Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer:a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol,2012,13:181-188. DOI: 10.1016/S1470-2045(11)70301-1
    [37]
    Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO):a randomised, open-label, non-comparative phase 2 trial[J]. Lancet Oncol,2014,15:819-828. DOI: 10.1016/S1470-2045(14)70212-8
    [38]
    Ferraro D, Goldstein D, O'Connell RL, et al. TACTIC:a multicentre, open-label, single-arm phase Ⅱ trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer[J]. Cancer Chemother Pharmacol,2016,78:361-367. DOI: 10.1007/s00280-016-3089-4
    [39]
    Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer:A randomized phase 2 trial (Vecti-BIL study)[J].Cancer,2016,122:574-581. DOI: 10.1002/cncr.29778
    [40]
    Kwak EL, Shapiro GI, Cohen SM, et al. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation[J]. Cancer,2013,119:3043-3051. DOI: 10.1002/cncr.28120
    [41]
    Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers:results of an early phase Ⅱ study with lapatinib[J]. Oncology,2012,82:175-179. DOI: 10.1159/000336488
    [42]
    Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer[J]. J Hematol Oncol,2015,8:58. DOI: 10.1186/s13045-015-0155-z
    [43]
    Giatromanolaki A, Sivridis E, Simopoulos C, et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas[J]. J Surg Oncol,2006,94:242-247. DOI: 10.1002/jso.20443
    [44]
    Iyer RV, Pokuri VK, Groman A, et al. A Multicenter Phase Ⅱ Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer[J]. Am J Clin Oncol,2018,41:649-655. DOI: 10.1097/COC.0000000000000347
    [45]
    Larsen FO, Markussen A, Diness LV, et al. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer:A Phase Ⅱ Study[J]. Oncology,2018,94:19-24.
    [46]
    Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03):a randomised phase 2 trial[J]. Lancet Oncol,2015,16:967-978. DOI: 10.1016/S1470-2045(15)00139-4
    [47]
    Krege S, Rexer H, vom Dorp F, et al. Prospective randomized double-blind multicentre phase Ⅱ study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer:SUSE (AUO-AB 31/05)[J]. BJU Int,2014,113:429-436. DOI: 10.1111/bju.12437
    [48]
    Lee JK, Capanu M, O'Reilly EM, et al. A phase Ⅱ study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas[J]. Br J Cancer,2013,109:915-919. DOI: 10.1038/bjc.2013.432
    [49]
    Yi JH, Thongprasert S, Lee J, et al. A phase Ⅱ study of sunitinib as a second-line treatment in advanced biliary tract carcinoma:a multicentre, multinational study[J]. Eur J Cancer,2012,48:196-201. DOI: 10.1016/j.ejca.2011.11.017
    [50]
    Santoro A, Gebbia V, Pressiani T, et al. A randomized, multicenter, phase Ⅱ study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer:the VanGogh study[J]. Ann Oncol,2015,26:542-547. DOI: 10.1093/annonc/mdu576
    [51]
    Finn RS, Ahn DH, Javle MM, et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer[J]. Invest New Drugs,2018,36:1037-1043. DOI: 10.1007/s10637-018-0600-2
    [52]
    Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 muta-tions in cholangiocarcinoma:a systematic literature review[J]. J Gastrointest Oncol,2019,10:751-765. DOI: 10.21037/jgo.2019.03.10
    [53]
    Saha SK, Gordan JD, Kleinstiver BP, et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma[J]. Cancer Discov,2016,6:727-739. DOI: 10.1158/2159-8290.CD-15-1442
    [54]
    Javle M, Lowery M, Shroff RT, et al. Phase Ⅱ Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma[J]. J Clin Oncol,2018,36:276-282.
    [55]
    Farshidfar F, Zheng S, Gingras MC, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles[J]. Cell Rep,2017, 18:2780-2794. DOI: 10.1016/j.celrep.2017.02.033
    [56]
    Meric-Bernstam F, Arkenau H, Tran B, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors[J]. Ann Oncol,2018,29:ix46-ix66.
    [57]
    Chae H, Kim D, Yoo C, et al. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer:DNA damage repair gene mutations as a predictive biomarker[J]. Eur J Cancer,2019,120:31-39. DOI: 10.1016/j.ejca.2019.07.022
    [58]
    Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma:A Multicenter Retrospective Study[J]. Oncologist, 2017,22:804-810. DOI: 10.1634/theoncologist.2016-0415
    [59]
    Xie Y, Jiang Y, Yang XB, et al. Response of BRCA1-mutated gallbladder cancer to olaparib:A case report[J]. World J Gastroenterol,2016,22:10254-10259. DOI: 10.3748/wjg.v22.i46.10254
    [60]
    Shen J, Peng Y, Wei L, et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors[J]. Cancer Discov,2015,5:752-767. DOI: 10.1158/2159-8290.CD-14-0849
    [61]
    Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015,47:1003-1010. DOI: 10.1038/ng.3375
    [62]
    Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science,2017,357:409-413. DOI: 10.1126/science.aan6733
    [63]
    Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramuciru-mab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer:Nonrandomi-zed, Open-Label, Phase I Trial (JVDF)[J]. Oncologist,2018,23:1407-e136. DOI: 10.1634/theoncologist.2018-0044
    [64]
    Lin J, Shi W,Zhao S,et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma(ICC):Preliminary data and correlation with next-generation sequencing[J].J Clin Oncol,2018,36:Abstract 500.
    [65]
    Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer:a non-randomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4:611-621. DOI: 10.1016/S2468-1253(19)30086-X
    • Related Articles

  • Related Articles

    [1]ZHANG Ning, YANG Chenhao, ZHOU Liangrui, SUN Xiaohong, LIU Xiaohong, KANG Lin, LI Ji, LI Hailong. Cronkhite-Canada Syndrome Combined with Asymptomatic Novel Coronavirus Infection: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 406-412. DOI: 10.12290/xhyxzz.2023-0476
    [2]LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
    [3]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [4]ZHAO Lidan, MENG Xia, XU Haojie, ZHANG Fengchun. Prospect of Gut Microbiota-based Intervention in Autoimmune Disease Control[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 740-746. DOI: 10.12290/xhyxzz.2022-0245
    [5]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [6]QIN Yongwen, BAI Yuan. History and Development of Interventional Devices forCongenital Heart Diseases in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 309-312. DOI: 10.12290/xhyxzz.2021-0148
    [7]XIAO Jiawang, ZHU Xianyang. Evolution of Interventional Treatment of Congenital Heart Disease in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 303-308. DOI: 10.12290/xhyxzz.2021-0157
    [8]Xiao-yun ZHANG, Jian-yu HAO. PTEN and Digestive Organ Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 300-304. DOI: 10.3969/j.issn.1674-9081.2017.05.020
    [9]Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006
    [10]Jie LIU, Yue-ping ZENG, Chun-xia HE, Qin LONG, Hong-zhong JIN, Qiu-ning SUN. Corticosteroids plus Intravenous Immunoglobulin in the Treatment of 7 Cases with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 381-385. DOI: 10.3969/j.issn.1674-9081.2012.04.004

  • Cited by

    Periodical cited type(9)

    1. 容逍，王丽芸，朱笔挥，邱逦. 超声医学前沿应用的研究生教学课程建设探讨. 临床医学研究与实践. 2024(23): 191-194 .
    2. 吴宏迪，沈焕. 下肢动静脉畸形的介入治疗. 当代医学. 2022(03): 72-74 .
    3. 张峥，李润霞. MSCT、超声检查在筛查精神分裂症患者下肢血管病变中的应用. 中国CT和MRI杂志. 2022(03): 180-182 .
    4. 张炎锋. 外周血管介入治疗肾动脉狭窄对患者肾功能、心功能以及血清ET-1、Scr水平的影响. 罕少疾病杂志. 2022(05): 69-71 .
    5. 李雪峰，梁洁，袁暾. 镍钛合金血管支架植入后再狭窄的组织病理评价研究. 医疗装备. 2022(10): 1-6 .
    6. 李妍，彭丽丽，魏莹，曹晓静，赵朕龙，于明安. 甲状旁腺功能亢进症微波消融治疗并发症的原因和护理. 循证护理. 2021(07): 942-944 .
    7. 刘桃桃，杨芳. 超声影响血小板生物活性的研究. 生物医学工程学杂志. 2021(04): 709-715 .
    8. 唐文波，都晓英，高涌，徐超. 超声引导下腔静脉滤器置入及临床应用的可行性研究. 蚌埠医学院学报. 2020(09): 1201-1204 .
    9. 李晖，卢肖媚，陈杰桓，郑楠，王涛. 优质综合护理干预在超声介入手术中的应用效果. 国际医药卫生导报. 2020(16): 2466-2469 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (440) PDF downloads (210) Cited by(9)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close